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BACKGROUND: On the base of the microRNA (miRNA) expression signature of bladder cancer (BC), we found that miR-1 and
miR-133a were significantly downregulated in BC. In this study, we focussed on the functional significance of miR-1 and miR-133a in
BC cell lines and identified a molecular network of these miRNAs.
METHODS AND RESULTS: We investigated the miRNA expression signature of BC clinical specimens and identified several
downregulated miRNAs (miR-133a, miR-204, miR-1, miR-139-5p, and miR-370). MiR-1 and miR-133a showed potential role of
tumour suppressors by functional analyses of BC cells such as cell proliferation, apoptosis, migration, and invasion assays. Molecular
target searches of these miRNAs showed that transgelin 2 (TAGLN2) was directly regulated by both miR-1 and miR-133a. Silencing
of TAGLN2 study demonstrated significant inhibitions of cell proliferation and increase of apoptosis in BC cell lines. The
immunohistochemistry showed a positive correlation between TAGLN2 expression and tumour grade in clinical BC specimens.
CONCLUSIONS: The downregulation of miR-1 and miR-133a was a frequent event in BC, and these miRNAs were recognised as
tumour suppressive. TAGLN2 may be a target of both miRNAs and had a potential oncogenic function. Therefore, novel molecular
networks provided by miRNAs may provide new insights into the underlying molecular mechanisms of BC.
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Bladder cancer (BC) is the fourth most common tumour diagnosed
and the second most common cause of death in patients with
genitourinary tract malignancies worldwide (Parkin et al, 2005;
Jemal et al, 2010). In Japan, the age-standardised mortality rate of
BC has remained relatively stable in men but has increased slightly
since 1993 in women (Qiu et al, 2009). There have been significant
advances in treatment, including surgical techniques and adjuvant
chemotherapy; however, BC continues to be a common disease
with high mortality (Shirodkar and Lokeshwar, 2009). Therefore,
new treatment modalities based on novel molecular networks
in BC are desired.
MicroRNAs (miRNAs) are a class of small non-coding
RNA molecules of 20–22 nucleotides that have a critical role in
a variety of biological processes including development, differen-
tiation, apoptosis, and cell proliferation. They regulate gene
expression through translational repression and mRNA degrada-
tion. Although their biological functions remain largely unknown,
recent studies suggest that miRNAs contribute to the development
of various types of cancer (Ryan et al, 2010). A growing body of
evidence indicates that miRNAs are aberrantly expressed in many
human cancers, and they may function as oncogenes and tumour
suppressors. Upregulated miRNAs could function as oncogenes
by negatively regulating tumour-suppressor genes, whereas down-
regulated miRNAs could act as tumour suppressors, inhibiting
cancers by regulating oncogenes (Lu et al, 2005; Calin and Croce,
2006; Ambs et al, 2008; Childs et al, 2009). Bioinformatic
predictions indicate that miRNAs regulate 430% of the protein
coding genes (Filipowicz et al, 2008). It is estimated that B1000
miRNAs exist in the vertebrate genome. So far, 1048 human
miRNAs are registered at miRBase release 16.0 (http://microrna.
sanger.ac.uk/).
MiR-1 and miR-133a were among the top five downregulated
miRNAs in our screening. MiR-1 and miR-133a are muscle-
enriched miRNAs that inhibit proliferation of progenitor cells and
promote myogenesis by targeting histone deacetylase (HDAC4)
and serum response factor (SRF), respectively (Chen et al, 2006).
Recently, miR-1 and miR-133a have been reported to be down-
regulated in various cancers and to have tumour-suppressive
functions (Datta et al, 2008; Nasser et al, 2008; Yan et al, 2009;
Uchida et al, 2010; Chiyomaru et al, 2010a). We have reported that
miR-133a directly regulated oncogenic FSCN1, LASP1, and GSTP1
genes in human BC (Uchida et al, 2010; Chiyomaru et al, 2010a,b).
We recognised that miR-1 and miR-133a are located on the same
chromosomal loci (18q11.2 and 20q13.33) (Chiyomaru et al,
2010b). Like this, several miRNAs are located on the same
chromosomal region, in a so-called ‘cluster’. Recent studies
demonstrated that miR-17-92 cluster and miR-221/222 cluster,
which harbour oncogenic miRNAs, had important roles in several
Received 22 October 2010; revised 6 January 2011; accepted 11 January
2011; published online 8 February 2011
*Correspondence: Dr T Chiyomaru;
E-mail: chiyo@m2.kufm.kagoshima-u.ac.jp
British Journal of Cancer (2011) 104, 808–818
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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However, the functional roles of the target genes regulated by these
miRNA clusters have not been thoroughly investigated.
The aim of this study was to investigate whether miR-1 has
tumour-suppressive function in BC cell lines and to find common
target genes of miR-1 and miR-133a. We focussed on transgelin 2
(TAGLN2), which was one of the most downregulated genes in
oligo-microarray studies using an miR-1 transfectant and is a
putative target gene of miR-1 and miR-133a as suggested by web-
based software. The functional role of TAGLN2 has not yet been
determined. Previous studies have reported that high expressions
of TAGLN2 were observed in various human malignancies (Chen
et al, 2005; Shi et al, 2005; Huang et al, 2006; Rho et al, 2009; Zhang
et al, 2010). We hypothesised that miR-1 and miR-133a directly
regulate TAGLN2, which may have an oncogenic function in BC.
We performed a luciferase reporter assay to determine whether
TAGLN2 mRNA is actually targeted by miR-1 and miR-133a and
a loss-of-function study using BC cell lines to investigate the
functional roles of TAGLN2 in BC.
MATERIALS AND METHODS
Clinical specimens and cell culture
Tissue specimens for miRNA screening using a low-density array
(LDA) were from 11 BC patients who had undergone cystectomy
or transurethral resection of bladder tumours (TUR-BT) at
Kagoshima University Hospital between 2007 and 2008. The tissue
specimens for quantitative RT–PCR were from 23 BC patients who
had received cystectomy or TUR-BT at Kagoshima University
Hospital between 2006 and 2009. The patients’ backgrounds and
clinicopathological characteristics are summarised in Supplemen-
tary Table 1. Normal bladder epitheliums (NBEs) were derived
from patients with noncancerous disease. These specimens were
staged according to the American Joint Committee on Cancer/
Union Internationale Contre le Cancer tumour-node-metastasis
classification and histologically graded (Sobin and Wittekind,
2002). Our study was approved by the Bioethics Committee of
Kagoshima University; written previous informed consent and
approval were given by these patients.
We used two human BC cell lines: BOY, which was established
in our laboratory from an Asian male patient aged 66 years who
was diagnosed with stage III BC with lung metastasis; and T24,
which was invasive and obtained from the American Type Culture
Collection. These cell lines were maintained in a minimum
essential medium (MEM) supplemented with 10% fetal bovine
serum in a humidified atmosphere of 5% CO2 and 95% air at 371C.
Tissue collection and RNA extraction
Tissues were immersed in RNAlater (QIAGEN, Valencia, CA, USA)
and stored at  201C until the RNA extraction. Total RNA
including miRNA was extracted using the mirVana miRNA
isolation kit (Ambion, Austin, TX, USA) following the manu-
facturer’s protocol. The integrity of the RNA was checked with
RNA 6000 Nano Assay Kit and a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
MiRNA expression signatures and data normalisation
MicroRNA expression patterns were evaluated using the TaqMan
LDA Human microRNA Panel v2.0 (Applied Biosystems, Foster
City, CA, USA). The assay was composed of two steps: generation
of cDNA by reverse transcription and a TaqMan real-time PCR
assay. The description of real-time PCR and the list of human
miRNAs can be found on the company’s website (http://www.
appliedbiosystems.com). An analysis of relative miRNA expression
data was performed using GeneSpring GX version 7.3.1 software
(Agilent Technologies) according to the manufacturer’s instruc-
tions. A cutoff P-value of o0.05 was used to narrow down the
candidates after global normalisation of the raw data. After global
normalisation, additional normalisation was done by RNU48 and
MammU6.
Quantitative real-time RT–PCR
TaqMan probes and primers for TAGLN2 (P/N: Hs00761239_m1;
Applied Biosystems) were assay-on-demand gene expression
products. All reactions were performed in duplicate and a negative
control lacking cDNA was included. We followed the manufac-
turer’s protocol for PCR conditions. Stem-loop RT–PCR (TaqMan
MicroRNA Assays; P/N: PM10617 for miR-1, and PM10413 for
miR-133a; Applied Biosystems) was used to quantitate miRNAs
according to the earlier published conditions (Ichimi et al, 2009).
To normalise the data for quantification of TAGLN2 mRNA and
the miRNAs, we used human GUSB (P/N: Hs99999908_m1; Applied
Biosystems) and RNU48 (P/N: 001006; Applied Biosystems),
respectively, and the DDCt method was employed to calculate the
fold change. As a control RNA, we used Premium Total RNA from
normal human bladder (AM7990; Applied Biosystems).
Mature miRNA and siRNA transfection
As described elsewhere (Ichimi et al, 2009), the BC cell lines were
transfected with Lipofectamine RNAiMAX transfection reagent
(Invitrogen, Carlsbad, CA, USA) and Opti-MEM (Invitrogen) with
10nM of mature miRNA molecules. Pre-miR and negative-control
miRNA (Applied Biosystems) were used in the gain-of-function
experiments, whereas TAGLN2 siRNA (Cat no. HSS144745 and
HSS144746; Invitrogen) and negative-control siRNA (D-001810-10;
Thermo Fisher Scientific, Waltham, MA, USA) were used in the
loss-of-function experiments. Cells were seeded in a 10-cm dish
for protein extraction (8 10
5 per dish), in a six-well plate for
apoptosis (10 10
4 per well) and for wound healing assay
(20 10
4 per well), in a 24-well plate for mRNA extraction and
luciferase reporter assay (5 10
4 per well), and in a 96-well plate
for XTT assay (3000 per well).
Cell proliferation, migration, and invasion assays
Cell proliferation was determined using an XTT assay (Roche
Applied Sciences, Tokyo, Japan) performed according to the
manufacturer’s instructions. Cell migration activity was evaluated
by wound healing assay. Cells were plated in six-well dishes, and
the cell monolayer was scraped using a P-20 micropipette tip. The
initial gap length (0h) and the residual gap length 24h after
wounding were calculated from photomicrographs. A cell invasion
assay was carried out using modified Boyden Chambers consisting
of transwell-precoated matrigel membrane filter inserts with 8-mm
pores in 24-well tissue culture plates (BD Biosciences, Bedfold,
MA, USA). Minimum essential medium containing 10% fetal
bovine serum in the lower chamber served as the chemoattractant
as described previously (Chiyomaru et al, 2010a). All experiments
were performed in triplicate.
Apoptosis analysis
The BC cell lines transiently transfected with transfection reagent
only (mock), si-control, si-TAGLN2, miR-control, miR-1,o r
miR-133a in six-well tissue culture plates as described earlier were
harvested 72h after transfection by trypsinisation and washed
in cold PBS. Double staining with FITC-Annexin V and propidium
iodide (PI) was carried out using the FITC Annexin V Apoptosis
Detection Kit (BD Biosciences) according to the manufacturer’s
recommendations and immediately analysed within an hour by flow
cytometry (FACScan; BD Biosciences). Cells were discriminated
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totic cells by the CellQuest software (BD Biosciences), and then
the percentages of early apoptotic and apoptotic cells from
each experiment were compared. Experiments were done in
triplicate.
Target gene search for miR-1
Oligo-microarray Human 44K (Agilent) was used for expression
profiling in miR-1-transfected BC cell lines (BOY and T24) in
comparison with miR-negative control transfectant, as previously
described (Chiyomaru et al, 2010a). Briefly, hybridisation and
washing steps were performed in accordance with the manufac-
turer’s instructions. The arrays were scanned using a Packard GSI
Lumonics ScanArray 4000 (PerkinElmer, Boston, MA, USA). The
data obtained were analysed with DNASIS array software (Hitachi
Software Engineering, Tokyo, Japan), which converted the signal
intensity for each spot into text format. The Log2 ratios of the
median subtracted background intensity were analysed. Data from
each microarray study were normalised by global normalisation.
The predicted target genes and their miRNA binding site seed
regions were investigated using TargetScan (release 5.1, http://
www.targetscan.org/). The sequences of the predicted mature
miRNAs were confirmed using miRBase (release 16.0, September
2010; http://microrna.sanger.ac.uk/).
Western blots
After 3 days of transfection, protein lysate (20mg) was separated by
NuPAGE on 4–12% bis-tris gel (Invitrogen) and transferred into a
polyvinylidene fluoride membrane. Immunoblotting was done
with diluted (1:150) polyclonal TAGLN2 antibody (HPA001925;
Sigma-Aldrich, St Louis, MO, USA) and GAPDH antibody
(MAB374; Chemicon, Temecula, CA, USA). The membrane was
washed and then incubated with goat anti-rabbit IgG (HþL)-HRP
conjugate (Bio-Rad, Hercules, CA, USA). Specific complexes were
visualised with an echochemiluminescence (ECL) detection system
(GE Healthcare, Little Chalfont, UK), and the expression level of
these genes was evaluated using ImageJ software (ver. 1.43; http://
rsbweb.nih.gov/ij/index.html).
Plasmid construction and dual-luciferase reporter assay
The miRNA target sequences were inserted between the XhoI–
PmeI restriction sites in the 30UTR of the hRluc gene in the
psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). Primer
sequences for full-length 30UTR of TAGLN2 mRNA (50-ATCGCTC
GAGACAGATGGGCACCAACCGCG-30 and 50-CTCTAGGTTTAAA
CATCTTCCTCAAGCCCCAGAC-30) were designed. Specific miRNA
target sequences (40bp length, Supplementary Table 2) for miR-1
and miR-133a were artificially synthesised and inserted in the
vector. Following that, T24 cells were transfected with 15ng
of vector, 10nM of miRNA, and 1ml of Lipofectamine 2000
(Invitrogen) in 100ml of Opti-MEM (Invitrogen). The activities
of firefly and Renilla luciferases in cell lysates were determined
with a dual-luciferase assay system (E1910; Promega). Normalised
data were calculated as the quotient of Renilla/firefly luciferase
activities.
Immunohistochemistry
A tissue microarray of 47 urothelial carcinomas and 8 normal
bladders was obtained from US Biomax, Inc. (BL208; Rockville,
MD, USA). Detailed information on all tumour specimens can be
found at http://www.biomax.us/index.php. Immunostaining was
done on the tissue microarray following the manufacturer’s
protocol. The primary rabbit polyclonal antibodies against
TAGLN2 (Sigma-Aldrich) were diluted by 1:25. The slides were
treated with biotinylated anti-rabbit IgG (HþL) made in goat
(Vector Laboratories, Burlingame, CA, USA). Diaminobenzidine-
hydrogen peroxide (Sigma-Aldrich) was the chromogen, and the
counterstaining was done with 0.5% haematoxylin. The positivity
of endothelia served as an inner positive control. Immunostaining
was evaluated according to a scoring method as described
previously (Zhang et al, 2010). Each case was scored on the basis
of the intensity and area of staining. The intensity of staining was
graded on the following scale: 0, no staining; 1þ, mild staining;
2þ, moderate staining; and 3þ, intense staining. The area
of staining was evaluated as follows: 0, no staining of
cells in any microscopic fields; 1þ, o30% of cells stained
positive; 2þ, 30–60% stained positive; and 3þ, 460% stained
positive. A combined staining score (intensityþextension) of p2
was low expression, a score between 3 and 4 was moderate
expression, and a score between 5 and 6 was high expression.
Statistical analysis
The relationship between two variables and the numerical values
obtained by real-time RT–PCR was analysed using the Mann–
Whitney U-test. The relationship among three variables and the
numerical values was analysed using the Bonferroni-adjusted
Mann–Whitney U-test. The w
2-test was used to evaluate the
relationships between the immunohistochemical score of TAGLN2
expression and clinicopathological factors. Expert StatView
analysis software (version 4; SAS Institute Inc., Cary, NC, USA)
was used in both cases. In the comparison among three variables, a
nonadjusted statistical level of significance of Po0.05 corresponds
to a Bonferroni-adjusted level of Po0.0167.
RESULTS
Identification of downregulated miRNAs in BC by miRNA
expression signatures
We evaluated mature miRNA expression levels of 11 BC and 5 NBE
specimens by miRNA expression signatures. A total of 41 and 19
downregulated miRNAs were selected after the normalisation
using RNU48 and MammU6, respectively (Supplementary Tables 3
and 4). The 17 miRNAs were commonly downregulated with
RNU48 and MammU6 normalisation (Table 1). The top five
miRNAs (miR-133a, miR-204, miR-1, miR-139-5p, and miR-370)i n
the list were subjected to further study.
Table 1 Downregulated microRNAs in bladder cancer (BC)
Fold change
microRNA P-value Normal Cancer Cancer/normal
hsa-miR-133a 3.50E–02 1.17E–01 2.48E–03 2.12E–02
hsa-miR-204 4.50E–02 4.51E–03 2.08E–04 4.61E–02
hsa-miR-1 9.40E–03 1.52E–03 7.16E–05 4.72E–02
hsa-miR-139-5p 1.71E–04 8.31E–02 4.65E–03 5.60E–02
hsa-miR-370 2.37E–02 8.95E–04 8.26E–05 9.23E–02
hsa-miR-133b 3.60E–02 1.78E–03 1.26E–04 7.06E–02
hsa-miR-574-3p 6.11E–04 3.25E–01 3.63E–02 1.12E–01
hsa-miR-376c 2.57E–03 1.44E–02 1.91E–03 1.32E–01
hsa-miR-214 2.62E–03 5.08E–02 7.29E–03 1.43E–01
hsa-let-7c 1.34E–03 4.70E–03 7.16E–04 1.52E–01
hsa-miR-140-3p 6.29E–03 1.73E–02 2.96E–03 1.72E–01
hsa-miR-134 7.02E–04 3.54E–03 6.69E–04 1.89E–01
hsa-miR-411 1.43E–03 4.58E–03 1.05E–03 2.29E–01
hsa-miR-218 1.83E–03 1.66E–02 4.06E–03 2.44E–01
hsa-miR-196b 6.14E–03 2.76E–02 7.56E–03 2.74E–01
hsa-miR-186 8.04E–04 8.68E–02 3.10E–02 3.57E–01
hsa-miR-320 3.81E–02 2.34E–01 9.70E–02 4.14E–01
miR-1 and miR-133a as tumour suppressors in BC
H Yoshino et al
810
British Journal of Cancer (2011) 104(5), 808–818 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sDetection of miR-133a, miR-204, miR-1, miR-139-5p, and
miR-370 expression by quantitative stem-loop RT–PCR
Quantitative stem-loop RT–PCR demonstrated that the expression
levels of the top five miRNAs (miR-133a, miR-204, miR-1,
miR-139-5p, and miR-370) were significantly lower in 23 BC
specimens in comparison with 10 NBEs (Po0.005; Figure 1). These
miRNA expressions were significantly lower in BC cell lines
(BOY and T24) in comparison with the normal human bladder
RNA (Po0.0001; Figure 2A).
Effect of the downregulated miRNA transfection on cell
proliferation, migration activity, and invasion in BC cell
lines
To investigate the functional role of the five selected miRNAs, we
performed gain-of-function studies using the miRNA transfec-
tants. The XTT assay showed significant cell proliferation
inhibitions in miR-1 and miR-133a transfectants in comparison
with the miR-control transfectants (percentage of cell viability for
BOY: 59.9±1.4, 64.1±1.4, and 100.0±1.2, respectively, Po0.0001;
and for T24: 43.3±0.6, 62.4±0.7, and 100.0±0.7, respectively,
Po0.0001), but no significant inhibition was observed in other
miRNA transfectants except the miR-204-transfected BOY cell line
(Figure 2B). The wound healing assay showed significant cell
migration inhibitions in miR-1 and miR-133a transfectants in
comparison with the controls (percentage of wound closure for
BOY; 41.4±2.5, 71.3±4.4, and 100.0±3.2, respectively, Po0.0001;
and for T24: 26.0±2.4, 65.2±3.9, and 100.0±3.2, respectively,
Po0.0001), but no significant inhibition was observed in other
miRNA transfectants except miR-370-transfected BOY cell line
(Figure 2C). Matrigel invasion assay demonstrated that invading
cell numbers were significantly decreased in both miR-1- and
miR-133a-transfected BOY cell lines and miR-1-transfected T24
cell line in comparison with the controls (percentage of cell inva-
sion for BOY: 23.4±3.0, 57.3±8.9, and 100.0±10.0, respectively,
Po0.0001; and for T24: 43.4±4.8, 96.5±4.4, and 100.0±3.8,
respectively, Po0.0001; the miR-1 transfectant vs control), but no
significant inhibition was observed in other miRNA transfectants
except the miR-370-transfected BOY cell line (Figure 2D). To
evaluate the simultaneous effect of miR-1 and miR-133a, we
evaluated another XTT assay by using miR-1 and miR-133a
co-transfected BOY and T24 cell lines. We found similar effects of
cell viability inhibition by the transfectants in comparison with
that of each miR-1 or miR-133a transfectants (Supplementary
Figure 1). Because miR-1 and miR-133a transfection had a
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miR-370) transfectants: (B) cell proliferation determined by the XTT assay;
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BOY and T24 cell lines transfected with the miRNAs. *Po0.005;
**Po0.0001.
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miRNAs, they were subjected to further analyses as the leading
candidates for tumour-suppressive miRNAs in BC.
MiR-1 induced apoptosis in BC cell lines
Cell apoptosis in miR-1 transfectants was detected using flow
cytometry. As shown by representative images in Figure 3A, the
apoptotic cell fractions (early apoptotic and apoptotic; lower right
and upper right, respectively) were greater in miR-1 transfectants
than in miR-control transfectants (BOY and T24). As shown in
Figure 3B, miR-1 transfection induced apoptosis in BC cell lines
(BOY, 3.31±0.51 and 1.00±0.20; T24, 1.70±0.08 and 1.00±0.17,
respectively, Po0.05). In terms of miR-133a, we previously
demonstrated that miR-133a transfection also induced apoptosis
in the same BC cell lines (Uchida et al, 2010).
Gene expression profile identifying downregulated genes
in miR-1 transfectant
To gain further insight into which genes are affected by miR-1
transfection, we performed gene expression analysis with miR-1
transfectants and the controls (BOY and T24 cells). A total of
18 genes were downregulated less than –4.0-fold in miR-1
transfectants compared with the controls (Table 2). The TargetS-
can program showed that 17 genes had putative target sites of miR-
1 in their 30UTR (Table 2). Previously, we had performed gene
expression analysis with miR-133a transfectants (Uchida et al,
2010), and the TAGLN2 gene was commonly listed in the top 10
downregulated genes in current (miR-1) and former (miR-133a)
signatures. Therefore, we focussed on the TAGLN2 gene as a
promising candidate targeted by both miR-1 and miR-133a. Entries
from the former and the current microarray data were approved by
the Gene Expression Omnibus (GEO) and were assigned GEO
accession numbers GSE19717 and GSE24782.
TAGLN2 expression in BC cell lines and TAGLN2 silencing
by miR-1 and miR-133a transfection
The quantitative real-time RT–PCR analysis showed that the
mRNA expression of TAGLN2 in the BOY and T24 cell lines
was more than two-fold higher than that in the normal human
bladder RNA (Figure 4A). To examine the functional role of
TAGLN2, we performed gain-of-function studies using miR-1
and miR-133a transfectant (BOY and T24) cell lines, and the
mRNA and protein expression levels of TAGLN2 were markedly
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Figure 3 (A) Apoptosis assay determined by flow cytometry. Early apoptotic cells can be seen in the bottom right quadrant and late are in the upper
right. (B) The normalised ratio of the apoptosis assay is shown in the histogram. *Po0.05.
Table 2 Downregulated genes in miR-1 transfectants
Fold change (log 2 ratio)
Entrez gene ID Symbol BOY T24 Average Description Target sites
23446 SLC44A1  3.86  3.69  3.77 Solute carrier family 44, member 1 +
114902 C1QTNF5  3.92  3.48  3.70 C1q and tumour necrosis factor related protein 5  
8407 TAGLN2  3.67  3.33  3.50 Transgelin 2 +
27230 SERP1  3.14  3.45  3.30 Stress-associated endoplasmic reticulum protein 1 +
359845 FAM101B  3.35  2.87  3.11 Family with sequence similarity 101, member B +
5756 TWF1  3.03  2.84  2.93 Twinfilin, actin-binding protein, homologue 1 (Drosophila) +
79794 C12orf49  3.04  2.69  2.86 Chromosome 12 open reading frame 49 þ
2697 GJA1  2.17  3.07  2.62 Gap junction protein, a 1, 43kDa +
4860 PNP  2.65  2.54  2.60 Purine nucleoside phosphorylase þ
57580 PREX1  2.07  2.44  2.26 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 +
8683 SFRS9  2.33  2.14  2.24 Splicing factor, arginine/serine-rich 9 +
23531 MMD  2.37  2.08  2.22 Monocyte to macrophage differentiation-associated +
2539 G6PD  2.31  2.06  2.18 Glucose-6-phosphate dehydrogenase +
84912 SLC35B4  2.31  2.05  2.18 Solute carrier family 35, member B4 +
7117 TMSL3  2.06  2.30  2.18 Thymosin-like 3 +
10487 CAP1  2.25  2.08  2.17 CAP, adenylate cyclase-associated protein 1 (yeast) +
5757 PTMA  2.25  2.04  2.15 Prothymosin, a +
378 ARF4  2.12  2.14  2.13 ADP-ribosylation factor 4 þ
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controls (Figure 4B).
TAGLN2 as a target of post-transcriptional repression by
miR-1 and miR-133a
We performed a luciferase reporter assay to determine whether
TAGLN2 mRNA has a target site for miR-1 and miR-133a. We used
a vector encoding full-length 30UTR of TAGLN2 mRNA and found
that the luminescence intensity was significantly reduced in the
miR-1 and miR-133a transfectant (Figure 5A). Furthermore, the
luminescence intensity significantly decreased at the three sites
targeted by miR-1 (position 71–77, 185–191, and 348–354) and
two sites targeted by miR-133a (position 214–220 and 242–248)
(Figure 5B).
Effect of TAGLN2 knockdown on cell proliferation,
invasion, and migration activity in BC cell lines
To examine the functional role of TAGLN2, we performed loss-of-
function studies using two different si-TAGLN2 transfections into
BOY and T24 cell lines. The mRNA and protein expression of
TAGLN2 was markedly repressed by these si-TAGLN2 transfec-
tions (Figure 6A). The XTT assay revealed significant cell
proliferation inhibition in the two si-TAGLN2 transfectants in
comparison with that in the untransfectants (mock) and the
si-control transfectants (percentage of cell viability for BOY:
69.0±1.3, 49.7±2.0, 100.0±2.6, and 104.6±2.9, respectively,
Po0.0001; and for T24: 77.4±1.4, 63.6±1.4, 100.0±1.2, and
100.5±1.6, respectively, Po0.0001; Figure 6B). The wound healing
assay also demonstrated significant cell migration inhibitions in
the two si-TAGLN2 transfectants compared with the counterparts
(percentage of wound closure for BOY: 36.0±7.3, 15.8±11.4,
100.0±3.0, and 98.2±2.6, respectively, Po0.0001; and for T24:
79.3±2.6, 43.6±3.2, 100.0±2.3, and 104.3±2.3, respectively,
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TAGLN2 was more than two-fold in BC cell lines compared with the normal
human bladder RNA. (B, upper) TAGLN2 mRNA expression after 24h of
transfection with 10nM of the miRNA (miR-1 and miR-133a). (B, lower)
TAGLN2 protein expression after 72h of transfection of miRNA. GAPDH
was used as a loading control. The protein expression level of TAGLN2
was also repressed in the transfectants.
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sPo0.0001; Figure 6C). The matrigel invasion assay demonstrated
that the number of invading cells was significantly decreased in the
two si-TAGLN2 transfectants compared with the counterparts
(percentage of cell invasion for BOY: 49.2±3.3, 6.2±2.7,
100.0±12.8, and 97.7±10.7, respectively, Po0.0005; and for T24:
45.7±4.0, 53.2±5.3, 100.0±6.0, and 108.3±7.6, respectively,
Po0.0001; Figure 6D).
TAGLN2 knockdown-induced apoptosis in BC cell lines
The apoptotic cell fractions were greater in the two si-TAGLN2
transfectants than those in the mock and si-control transfectant at
72h after transfection (relative to mock; BOY: 2.34±0.04,
2.84±0.05, 1.00±0.15, and 1.00±0.15, respectively, Po0.0001;
T24: 1.93±0.09, 2.70±0.12, 1.00±0.00, and 1.18±0.07, respec-
tively, Po0.0001; Figure 6E).
Immunohistochemistry of TAGLN2 in tissue microarray
Figure 7 shows representative results of immmunohistochemical
staining of TAGLN2. The TAGLN2 was strongly expressed in
several tumour lesions: A (Grade 1, T2bN0M0), B (Grade 2,
T3N0M0), C (Grade 3, T2N0M0), and D (Grade 3, metastatic
region), whereas no expression was observed in the normal tissue
(E); the expression score of tumours was significantly higher than
that of normal tissues (P¼0.0202). We found that there were
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Figure 6 (A, upper) TAGLN2 mRNA expression after 24h of transfection with 10nM of si-TAGLN2. TAGLN2 mRNA expression was repressed in
si-TAGLN2 transfectants. (A, lower) TAGLN2 protein expression after 72h of transfection of the siRNAs. GAPDH was used a loading control. (B–D)
TAGLN2-knockdown effects on BC cell viability by si-RNA. (B) Cell proliferation determined by the XTT assay; (C) cell migration activity determined by the
wound healing assay; and (D) cell invasion activity determined by the matrigel invasion assay in BOY and T24 cell lines transfected with si-TAGLN2.
*Po0.0005; **Po0.0001. (E) Apoptosis assay determined by flow cytometry. Early apoptotic cells can be seen in the bottom right quadrant and late are in
the upper right. The normalised ratio of the apoptosis assay is shown in the histogram. **Po0.0001.
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grade/metastasis (P¼0.0148 and P¼0.0145, respectively; Table 3).
DISCUSSION
In this study, we identified 17 downregulated miRNAs that
survived after three different normalisation methods. Among
them, we tested miR-133a, miR-204, miR-1, miR-139-5p, and
miR-370, which were the top five downregulated miRNAs.
Investigators had demonstrated that miR-204 was a tumour-
suppressive miRNA in head and neck tumour (Lee et al, 2010);
miR-139-5p was downregulated in endometrial serous adeno-
carcinoma (Hiroki et al, 2010); and miR-370 expression was
silenced by promoter hypermethylation in malignant human
cholangiocytes (Meng et al, 2008). The expression levels of the
five miRNAs were indeed downregulated in BC specimens as well
as in BC cell lines. However, we found typical tumour-suppressive
effects in miR-1- and miR-133a-transfected BC cell lines, and these
miRNAs were plausible to be critical for BC development.
The miR-1 and miR-133 are cardiac and skeletal muscle-specific,
bicistronic miRNAs transcriptionally controlled by some
major regulators of muscle differentiation (Chen et al, 2006;
Williams et al, 2009). These miRNAs have been reported to be
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sdownregulated in human malignancies (Datta et al, 2008; Nasser
et al, 2008; Yan et al, 2009; Uchida et al, 2010; Chiyomaru et al,
2010a). Ectopic expression of miR-1 in HCC, lung cancer, prostate
cancer, and rhabdomyosarcoma inhibited tumour cell growth
(Ambs et al, 2008; Datta et al, 2008; Nasser et al, 2008; Yan et al,
2009). However, the function of miR-1 in BC remains to be
elucidated. MiR-1 had an important role in the regulation of
apoptosis, which is involved in post-transcriptional repression of
BCL2 in cardiomyocyte (Tang et al, 2009). In cancer research
fields, ectopic miR-1 induced apoptosis through enhanced activa-
tion of caspases 3 and 7, cleavage of their substrate PARP-1, and
depletion of antiapoptotic Mcl-1 in lung cancer cells (Nasser et al,
2008). Consistent with previous studies, re-expression of miR-1 in
BC cell lines resulted in induction of apoptosis and reduced cell
viability in this study. Regarding miR-133a, previous studies
demonstrated that its expression was downregulated in pancreatic
ductal adenocarcinoma, oesophageal squamous cell carcinoma,
rhabdomyosarcoma, colorectal cancer, and squamous cell carci-
noma of the tongue (Bandre ´s et al, 2006; Szafranska et al, 2007;
Wong et al, 2008a,b; Arndt et al, 2009; Yan et al, 2009; Kano et al,
2010). MiR-133a inhibited proliferation and induced apoptosis and
directly bound to pyruvate kinase type M2 expression, which are
potent oncogenes (Wong et al, 2008b). However, there has been no
study concerning genes targeted by both miR-1 and miR-133a,
which are clustered on the same chromosomal loci in human
malignancies. In BC, we have reported that miR-133a had a critical
role in regulating oncogenic FSCN1, LASP1, and GSTP1 (Uchida
et al, 2010; Chiyomaru et al, 2010a,b) and have demonstrated for
the first time that LASP1 was the target of miR-1/miR-133a cluster
(Chiyomaru et al, 2010b). In this study, the TAGLN2 gene was
found to be another target of the miR-1/miR-133a cluster. It is
plausible that the miR-1/miR-133a cluster may have important
roles as tumour suppressors through downregulating these
oncogenic genes. However, we found no simultaneous effect of
cell viability inhibition by miR-1 and miR-133a co-transfection,
suggesting that each miRNA may strongly repress same target
× 100 × 200
Figure 7 Immunohistochemical staining of TAGLN2 in tissue specimens.
(A) Positively stained tumour lesion (Grade 1, T2bN0M0); (B) positively
stained tumour lesion (Grade 2, T3N0M0); (C) positively stained tumour
lesion (Grade 3, T2N0M0); (D) positive staining in metastatic BC cells of
metastatic region (Grade 3); (E) negative staining in normal urocustis tissue.
(A–D) Positive staining in tumour cells: weak (A), moderate (B), and
strong (C, D). Some microvessel walls also stained positive for TAGLN2
(A, B, E arrowheads).
Table 3 Relationships between TAGLN2 expression and clinicopatho-
logical factors in tissue microarray
TAGLN2 expression (score)
Characteristics n
Low
(0–2)
Moderate
(3 to 4)
High
(5 to 6) P-values
Normal and BC tissue
Normal 8 8 0 0 0.0202
Cancer 47 22 20 5
Age at presentation
465 years 17 9 6 2 0.7499
p65 years 30 13 14 3
Sex
Male 38 17 18 3 0.2635
Female 9 5 2 2
Histological grade
G1+G2 28 14 14 0 0.0148
G3 19 6 8 5
Tumour status
T1 10 5 4 1 0.9536
T2+T3+T4 28 15 11 2
Unknown 9
LN metastasis
N0 40 50 17 3 0.5195
N1 1 0 1 0
Unknown 6
Distant metastasis
M0 43 22 18 3 0.0145
M1 4 0 2 2
Abbreviations: TAGLN2¼transgelin 2; BC¼bladder cancer; LN¼lymph node.
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sgenes and no additional effect might be caused by the other
miRNA. Further investigations are necessary to elucidate the
simultaneous effect of the miR-1/miR-133a cluster. Our data
suggest that retrieved expression of miR-1/miR-133a clusters could
be a new therapeutic strategy for BC.
TAGLN2 contains a conserved actin-binding domain also known
as the calponin (a calcium-binding protein) homologue domain.
TAGLN and TAGLN3 are homologues of TAGLN2, and TAGLN3 is
a novel neuron-specific protein and has not been reported in
cancer (Ito et al, 2005). The protein encoded by the TAGLN gene is
an actin-binding protein like TAGLN2, found in fibroblasts and
smooth muscle. Overexpression of the TAGLN protein has been
observed in carcinomas of the stomach, liver, and oesophagus
(Rho et al, 2009). Although the function of TAGLN2 is unknown,
there have been a number of reports concerning the relationship
between TAGLN2 expression and tumourigenesis (Chen et al,
2005; Shi et al, 2005; Huang et al, 2006; Rho et al, 2009; Zhang et al,
2010). Overexpression of TAGLN2 was observed in HCC and
pancreatic cancer (Chen et al, 2005; Shi et al, 2005; Huang et al,
2006). Zhang et al (2010) demonstrated that increased TAGLN2
expression was correlated with lymph node metastasis, distant
metastasis, and the TNM classification in colorectal cancer.
We also found a significant correlation of TAGLN2 expression
with metastasis region and tumour grade despite of no correlation
with tumour stage. Our tissue microarray included no Ta tumour
and only four metastasis-positive patients. Studies for larger
number of samples with balanced pathological background are
needed to elucidate the precise correlation between TAGLN2
expression and clinicopathological parameters. These studies
have implied that TAGLN2 may represent a potential tumour
biomarker. We found that cell viability was markedly decreased in
TAGLN2 knockdown cells by inducing apoptosis, which suggests
that this molecule may have oncogenic function. However, it is still
unknown how TAGLN2, which is an actin-binding protein,
interacts with apoptosis. Further examinations are necessary to
elucidate this.
In summary, miR-1/miR-133a clusters may function as tumour
suppressors through repression of oncogenic TAGLN2 in BC.
MiR-1/miR-133a transfection and TAGLN2 knockdown resulted
in decreased BC cell viability and induction of apoptosis. Novel
molecular networks provided by miRNAs may provide new
insights into the underlying molecular mechanisms of BC.
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